These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1509 related items for PubMed ID: 25488124

  • 21. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR, Brooks NO, Mackel CE, Pani A, Stewart AP, Price LL, Barouch FC, Chang J, Marx JL.
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [Abstract] [Full Text] [Related]

  • 22. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS, Muecke J.
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [Abstract] [Full Text] [Related]

  • 23. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD.
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [Abstract] [Full Text] [Related]

  • 24. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
    Nomura Y, Yanagi Y.
    Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
    [Abstract] [Full Text] [Related]

  • 25. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
    Enders P, Muether PS, Hermann M, Ristau T, Fauser S.
    Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
    [Abstract] [Full Text] [Related]

  • 26. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I, Gianniou C, Dirani A.
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [Abstract] [Full Text] [Related]

  • 27. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.
    Heussen FM, Shao Q, Ouyang Y, Joussen AM, Müller B.
    Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):909-15. PubMed ID: 24362854
    [Abstract] [Full Text] [Related]

  • 28. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR.
    Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
    [Abstract] [Full Text] [Related]

  • 29. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB.
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [Abstract] [Full Text] [Related]

  • 30. Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.
    He L, Silva RA, Ayoub N, Moshfeghi DM, Leng T.
    Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):542-9. PubMed ID: 26057757
    [Abstract] [Full Text] [Related]

  • 31. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [Abstract] [Full Text] [Related]

  • 32. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC, Diabetic Retinopathy Clinical Research Network.
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [Abstract] [Full Text] [Related]

  • 33. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T.
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [Abstract] [Full Text] [Related]

  • 34. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP.
    Ophthalmic Epidemiol; 2016 Sep; 23(2):71-9. PubMed ID: 26855278
    [Abstract] [Full Text] [Related]

  • 35. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR, Nunes RP, Chen GW, Doshi RR, Dugar J, George MK, Kim BT, Lowrance MD, Modi D, Nahas Z, Gregori G, Yehoshua Z, Feuer W, Rosenfeld PJ.
    Ophthalmic Surg Lasers Imaging Retina; 2014 Sep; 45(6):526-33. PubMed ID: 25423632
    [Abstract] [Full Text] [Related]

  • 36. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H, Weber ML, Shah CP, Heier JS.
    Eur J Ophthalmol; 2014 Sep; 24(4):576-81. PubMed ID: 24706352
    [Abstract] [Full Text] [Related]

  • 37. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I.
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [Abstract] [Full Text] [Related]

  • 38. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB, Zebardast N, Huang JJ, Adelman RA.
    J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
    [Abstract] [Full Text] [Related]

  • 39. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S.
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [Abstract] [Full Text] [Related]

  • 40. Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism.
    Angermann R, Rauchegger T, Nowosielski Y, Seifarth C, Egger S, Kralinger MT, Kieselbach GF, Zehetner C.
    Acta Ophthalmol; 2021 Sep; 99(6):e869-e875. PubMed ID: 33326179
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 76.